2. Academic Validation
  3. Design, Synthesis, and Biological Evaluation of PKD Inhibitors

Design, Synthesis, and Biological Evaluation of PKD Inhibitors

  • Pharmaceutics. 2011;3(2):186-228. doi: 10.3390/pharmaceutics3020186.
Kara M George 1,  Marie-Céline Frantz,  Karla Bravo-Altamirano,  Courtney R Lavalle,  Manuj Tandon,  Stephanie Leimgruber,  Elizabeth R Sharlow,  John S Lazo,  Q Jane Wang,  Peter Wipf
Affiliations

Affiliation

  • 1 Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA.
PMID: 22267986 DOI: 10.3390/pharmaceutics3020186
Abstract

Protein kinase D (PKD) belongs to a family of serine/threonine kinases that play an important role in basic cellular processes and are implicated in the pathogenesis of several diseases. Progress in our understanding of the biological functions of PKD has been limited due to the lack of a PKD-specific inhibitor. The benzoxoloazepinolone CID755673 was recently reported as the first potent and kinase-selective inhibitor for this Enzyme. For structure-activity analysis purposes, a series of analogs was prepared and their in vitro inhibitory potency evaluated.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16698
    99.97%, CID797718 Analogue